Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) closed at $26.99 in the last session, up 1.28% from day before closing price of $26.65. In other words, the price has increased by $1.28 from its previous closing price. On the day, 0.34 million shares were traded. AMPH stock price reached its highest trading level at $27.39 during the session, while it also had its lowest trading level at $26.74.
Ratios:
We take a closer look at AMPH’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.19. For the most recent quarter (mrq), Quick Ratio is recorded 2.21 and its Current Ratio is at 3.29. In the meantime, Its Debt-to-Equity ratio is 0.87 whereas as Long-Term Debt/Eq ratio is at 0.85.
On May 12, 2025, JP Morgan Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $30.
Piper Sandler Downgraded its Overweight to Neutral on February 04, 2025, whereas the target price for the stock was revised from $66 to $36.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 01 ’25 when Petersen Floyd F. bought 500 shares for $26.74 per share.
Petersen Floyd F. sold 500 shares of AMPH for $15,492 on Sep 02 ’25. The Director now owns 76,531 shares after completing the transaction at $30.98 per share. On Sep 02 ’25, another insider, Petersen Floyd F., who serves as the Director of the company, bought 500 shares for $30.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMPH now has a Market Capitalization of 1254902144 and an Enterprise Value of 1678648192. As of this moment, Amphastar’s Price-to-Earnings (P/E) ratio for their current fiscal year is 10.10, and their Forward P/E ratio for the next fiscal year is 7.12. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.70. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.74 while its Price-to-Book (P/B) ratio in mrq is 1.66. Its current Enterprise Value per Revenue stands at 2.323 whereas that against EBITDA is 7.091.
Stock Price History:
The Beta on a monthly basis for AMPH is 0.75, which has changed by -0.4246546 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, AMPH has reached a high of $53.96, while it has fallen to a 52-week low of $20.39. The 50-Day Moving Average of the stock is 0.08%, while the 200-Day Moving Average is calculated to be -4.43%.
Shares Statistics:
According to the various share statistics, AMPH traded on average about 523.67K shares per day over the past 3-months and 557800 shares per day over the past 10 days. A total of 46.49M shares are outstanding, with a floating share count of 34.22M. Insiders hold about 26.39% of the company’s shares, while institutions hold 71.54% stake in the company. Shares short for AMPH as of 1757894400 were 4130306 with a Short Ratio of 7.89, compared to 1755216000 on 4134257. Therefore, it implies a Short% of Shares Outstanding of 4130306 and a Short% of Float of 17.849999999999998.
Earnings Estimates
A comprehensive evaluation of Amphastar Pharmaceuticals Inc (AMPH) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.91, with high estimates of $1.1 and low estimates of $0.74.
Analysts are recommending an EPS of between $3.57 and $3.1 for the fiscal current year, implying an average EPS of $3.32. EPS for the following year is $3.79, with 6.0 analysts recommending between $4.81 and $3.29.
Revenue Estimates
According to 6 analysts,. The current quarter’s revenue is expected to be $186.89M. It ranges from a high estimate of $193.9M to a low estimate of $177.1M. As of. The current estimate, Amphastar Pharmaceuticals Inc’s year-ago sales were $191.21MFor the next quarter, 6 analysts are estimating revenue of $195.39M. There is a high estimate of $210.8M for the next quarter, whereas the lowest estimate is $181M.
A total of 6 analysts have provided revenue estimates for AMPH’s current fiscal year. The highest revenue estimate was $749.6M, while the lowest revenue estimate was $710M, resulting in an average revenue estimate of $727.42M. In the same quarter a year ago, actual revenue was $731.97MBased on 6 analysts’ estimates, the company’s revenue will be $777.79M in the next fiscal year. The high estimate is $885.5M and the low estimate is $736.9M.
